State Street Corporation has filed a Schedule 13G with the SEC, revealing that it has acquired a significant stake in Biogen Inc. The filing indicates that State Street now beneficially owns 7,570,589 shares of Biogen's common stock, which represents approximately 5.1% of the company's total shares. This substantial ownership may influence Biogen's strategic decisions and operations as it moves forward.
Background
Biogen Inc., classified under SIC 2836 for Biological Products (No Diagnostic Substances), is a leading biotechnology company focused on discovering, developing, and delivering innovative therapies for neurological diseases. The company trades on the Nasdaq under the ticker symbol BIIB. Recent filings include a Schedule 13G on November 10, 2026, and a Form 10-Q on October 28, 2026.
What the Filing Says
The Schedule 13G filing, dated November 10, 2026, indicates that State Street holds a total of 7,570,589 shares of Biogen, with shared voting power of 4,863,692 shares. The filing states, "The securities referred to above were acquired and are held in the ordinary course of business." This suggests that State Street's acquisition was not intended to influence control over Biogen.
Impact
This development may affect Biogen's management and strategic direction, as significant shareholders can often sway company policies and initiatives. Additionally, State Street's involvement could prompt other investors to reassess their positions in Biogen and the broader biological products industry.
What's Next
The filing does not say what happens next regarding State Street's investment or Biogen's response to this increased ownership.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




